modelFusidicAcid
Extends from Pharmacolibrary.Drugs.ATC.S.S01AA13.
Information
| name: | FusidicAcid | |
| ATC code: | S01AA13 | route: | topical |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 1 | L |
| clearance: | 0.01 | L/h |
| other parameters in model implementation | ||
Fusidic acid is an antibiotic of the steroid class used to treat bacterial infections, particularly those caused by staphylococci, including methicillin-resistant Staphylococcus aureus (MRSA). It is mainly used for skin and eye infections and is formulated topically and systemically. For ocular use (ATC S01AA13), it is available as an ophthalmic gel or drops. Fusidic acid is approved and used in many countries today.
Pharmacokinetics
Estimated pharmacokinetic parameters for topical (ocular) administration in adults. No published compartmental pharmacokinetics models specific to ocular (ATC S01AA13) administration of fusidic acid were found. Most published PK data are from oral or intravenous use or systemic exposure studies.
References
Wadhwa, S, et al., & Katare, OP (2016). Liposomal fusidic acid as a potential delivery system: a new paradigm in the treatment of chronic plaque psoriasis. Drug delivery 23(4) 1204–1213. DOI:10.3109/10717544.2015.1110845 PUBMED:https://pubmed.ncbi.nlm.nih.gov/26592918
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)